Sébastien Dharancy

Sébastien Dharancy

Auto-generated profile, based on publicly available information

Sébastien Dharancy

Service d'Hépato-Gastroentérologie, Lille University Hospital, Lille, France

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Gastroenterology
Verified
Journal Article
Closed access
CDChristophe Duvoux
Christophe Duvoux
FRFrançoise Roudot–Thoraval
Françoise Roudot–Thoraval
TDThomas DECAENS
Thomas DECAENS
FPFabienne Pessione
Fabienne Pessione
HBHanaa Badran
Hanaa Badran
DCDaniel Cherqui
Daniel Cherqui

10 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PMPhilippe Mathurin
Philippe Mathurin
CMChristophe Moreno
Christophe Moreno
DSDidier Samuel
Didier Samuel
JDJérôme Dumortier
Jérôme Dumortier
JSJulia Salleron
Julia Salleron
JDJean-Charles Duclos-Vallée
Jean-Charles Duclos-Vallée
A 6-month abstinence from alcohol is usually required before patients with severe alcoholic hepatitis are considered for liver transplantation. Patients whose hepatitis is not responding to medical therapy have a 6-month survival rate of approximately 30%. Since most alcoholic hepatitis deaths occur within 2 months, early liver transplantation is attractive but controversial. We selected patients from seven centers for early liver transplantation. The patients had no prior episodes of alcoholic hepatitis and had scores of 0.45 or higher according to the Lille model (which calculates scores ranging from 0 to 1, with a score ≥0.45 indicating nonresponse to medical therapy and an increased risk of death in the absence of transplantation) or rapid worsening of liver function despite medical therapy. Selected patients also had supportive family members, no severe coexisting conditions, and a commitment to alcohol abstinence. Survival was compared between patients who underwent early liver transplantation and matched patients who did not. In all, 26 patients with severe alcoholic hepatitis at high risk of death (median Lille score, 0.88) were selected and placed on the list for a liver transplant within a median of 13 days after nonresponse to medical therapy. Fewer than 2% of patients admitted for an episode of severe alcoholic hepatitis were selected. The centers used 2.9% of available grafts for this indication. The cumulative 6-month survival rate (±SE) was higher among patients who received early transplantation than among those who did not (77±8% vs. 23±8%, P<0.001). This benefit of early transplantation was maintained through 2 years of follow-up (hazard ratio, 6.08; P=0.004). Three patients resumed drinking alcohol: one at 720 days, one at 740 days, and one at 1140 days after transplantation. Early liver transplantation can improve survival in patients with a first episode of severe alcoholic hepatitis not responding to medical therapy. (Funded by Société Nationale Française de Gastroentérologie.)

1 August 2015 in Gastroenterology
Verified
Journal Article
Closed access
GLGuillaume Lassailly
Guillaume Lassailly
RCRobert Caiazzo
Robert Caiazzo
DBDavid Buob
David Buob
MPMarie Pigeyre
Marie Pigeyre
HVHélène Verkindt
Hélène Verkindt
PMPhilippe Mathurin
Philippe Mathurin

20 March 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Nassim KamarNassim Kamar
Nassim Kamar
JIJacques Izopet
Jacques Izopet
STSimona Tripon
Simona Tripon
MBMichael Bismuth
Michael Bismuth
SHSophie Hillaire
Sophie Hillaire
VMVincent Mallet
Vincent Mallet
There is no established therapy for hepatitis E virus (HEV) infection. The aim of this retrospective, multicenter case series was to assess the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV viremia. We examined the records of 59 patients who had received a solid-organ transplant (37 kidney-transplant recipients, 10 liver-transplant recipients, 5 heart-transplant recipients, 5 kidney and pancreas–transplant recipients, and 2 lung-transplant recipients). Ribavirin therapy was initiated a median of 9 months (range, 1 to 82) after the diagnosis of HEV infection at a median dose of 600 mg per day (range, 29 to 1200), which was equivalent to 8.1 mg per kilogram of body weight per day (range, 0.6 to 16.3). Patients received ribavirin for a median of 3 months (range, 1 to 18); 66% of the patients received ribavirin for 3 months or less. All the patients had HEV viremia when ribavirin was initiated (all 54 in whom genotyping was performed had HEV genotype 3). At the end of therapy, HEV clearance was observed in 95% of the patients. A recurrence of HEV replication occurred in 10 patients after ribavirin was stopped. A sustained virologic response, defined as an undetectable serum HEV RNA level at least 6 months after cessation of ribavirin therapy, occurred in 46 of the 59 patients (78%). A sustained virologic response was also observed in 4 patients who had a recurrence and were re-treated for a longer period. A higher lymphocyte count when ribavirin therapy was initiated was associated with a greater likelihood of a sustained virologic response. Anemia was the main identified side effect and required a reduction in ribavirin dose in 29% of the patients, the use of erythropoietin in 54%, and blood transfusions in 12%. This retrospective, multicenter study showed that ribavirin as monotherapy may be effective in the treatment of chronic HEV infection; a 3-month course seemed to be an appropriate duration of therapy for most patients.

1 January 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
PNPierre Nahon
Pierre Nahon
VBValérie Bourcier
Valérie Bourcier
RLRichard Layese
Richard Layese
EAEtienne Audureau
Etienne Audureau
CCCarole Cagnot
Carole Cagnot
SHSophie Hillaire
Sophie Hillaire

1 January 2017 in Gastroenterology
Verified
Journal Article
Open access
PDF file
CBChristophe Bureau
Christophe Bureau
DTDominique Thabut
Dominique Thabut
FOFrédéric Oberti
Frédéric Oberti
SDSébastien Dharancy
Sébastien Dharancy
NCNicolas Carbonell
Nicolas Carbonell
JVJean Pierre Vinel
Jean Pierre Vinel
There is controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrhosis and refractory ascites. The high rate of shunt dysfunction with the use of uncovered stents counteracts the benefits of TIPS. We performed a randomized controlled trial to determine the effects of TIPS with stents covered with polytetrafluoroethylene in these patients. We performed a prospective study of 62 patients with cirrhosis and at least 2 large-volume paracenteses within a period of at least 3 weeks; the study was performed at 4 tertiary care centers in France from August 2005 through December 2012. Patients were randomly assigned to groups that received covered TIPS (n = 29) or large-volume paracenteses and albumin as necessary (LVP+A, n = 33). All patients maintained a low-salt diet and were examined at 1 month after the procedure then every 3 months until 1 year. At each visit, liver disease-related complications, treatment modifications, and clinical and biochemical variables needed to calculate Child-Pugh and Model for End-Stage Liver Disease scores were recorded. Doppler ultrasonography was performed at the start of the study and then at 6 and 12 months after the procedure. The primary study end point was survival without a liver transplant for 1 year after the procedure. A higher proportion of patients in the TIPS group (93%) met the primary end point than in the LVP+A group (52%) (P = .003). The total number of paracenteses was 32 in the TIPS group vs 320 in the LVP+A group. Higher proportions of patients in the LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01) or hernia-related complications (18% vs 0%; P = .01) than in the TIPS group. Patients in LVP+A group had twice as many days of hospitalization (35 days) as the TIPS group (17 days) (P = .04). The 1-year probability of remaining free of encephalopathy was 65% for each group. In a randomized trial, we found covered stents for TIPS to increase the proportion of patients with cirrhosis and recurrent ascites who survive transplantation-free for 1 year, compared with patients given repeated LVP+A. These findings support TIPS as the first-line intervention in such patients. ClinicalTrials.gov ID: NCT00222014.